Volitionrx (VNRX) Net Equity Issued and Repurchased (2011 - 2025)
Volitionrx's (VNRX) quarterly Net Equity Issued and Repurchased came in at $6.7 million in Q4 2025, up 231.36% YoY from $2.0 million in Q4 2024, and up 234.55% on a QoQ basis from $2.0 million in Q3 2025.
Volitionrx (VNRX) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
Volitionrx (VNRX) has 15 years of Net Equity Issued and Repurchased data on file, last reported at $6.7 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 231.36% year-over-year to $6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.2 million (up 30.01% YoY) and the FY2025 annual result came in at $11.2 million, up 30.01% from the prior year.
- Net Equity Issued and Repurchased grew to $6.7 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.3 million in Q1 2021 to a low of -$85567.0 in Q3 2023.
- A 5-year average of $4.8 million and a median of $2.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 581785633.33% in 2023, down 101.44% in 2023.
- Tracing VNRX's Net Equity Issued and Repurchased over 5 years: stood at $1.8 million in 2021, then plunged by 56.15% to $781794.0 in 2022, then surged by 231.59% to $2.6 million in 2023, then decreased by 21.82% to $2.0 million in 2024, then surged by 231.36% to $6.7 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $6.7 million (Q4 2025), $2.0 million (Q3 2025), and $62560.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Volitionrx | 1.19 Mn | -1.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.72 Mn |
| Dec 31, 2025 | 6.72 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 62,560.00 |
| Jun 30, 2025 | 62,560.00 |
| Mar 31, 2025 | 2.38 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 2.03 Mn |
| Dec 31, 2024 | 2.03 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 589,489.00 |
| Jun 30, 2024 | 589,489.00 |
| Mar 31, 2024 | 15,733.00 |
| Mar 31, 2024 | 15,733.00 |
| Dec 31, 2023 | 2.59 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | -85,567.00 |
| Sep 30, 2023 | -85,567.00 |